Signalpoint

← Full daily brief

Mass Tort brief

GLP-1 Blindness Claims Mount as Courts Open New PFAS Frontiers

Courts advance turnout gear lawsuits against 3M and DuPont, GLP-1 eye injury claims consolidate, and Meta's settlement reshapes algorithmic product liability.

Signalpoint TeamBrief

Mass Tort

Over 130 blindness lawsuits against Ozempic and Zepbound makers are consolidating in court — threatening the blockbuster commercial track record of GLP-1 treatments.

BackgroundGlucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications prescribed to millions worldwide for diabetes management and rapid weight loss. Medical researchers recently identified a statistical link between semaglutide and non-arteritic anterior ischemic optic neuropathy, a condition causing sudden blindness.

Points
  1. More than 130 federal personal injury lawsuits consolidated in Philadelphia accuse manufacturers of failing to alert physicians to optical nerve death risks.
  2. Novo Nordisk and Eli Lilly argue underlying conditions like obesity, sleep apnea, and hypertension confound the findings, insisting no clinical causation is established.
  3. While the European Medicines Agency designated vision loss as a rare potential adverse reaction, the US FDA has not required updated warning labels.
SourcesBoston 25 News: 'Boom, lights out': Massachusetts man shares sudden blindness journey after taking GLP-1 (opens in new tab)ChosunBiz: US lawsuits target GLP-1 drugs over vision loss as evidence remains mixed (opens in new tab)

Mass Tort

Judges cleared firefighter gear lawsuits against 3M and DuPont — opening a brand-new multi-district liability front focused on chemical protective clothing.

BackgroundPer- and polyfluoroalkyl substances, known as PFAS, are industrial chemicals valued for their heat and water resistance in protective fabrics. Because these compounds do not degrade naturally, they bioaccumulate inside human tissue and have been linked to multiple aggressive cancers.

Points
  1. The court denied defense motions to dismiss, ruling firefighters presented sufficient evidence that manufacturers knowingly distributed defective chemical-laden gear.
  2. The litigation expands into a newly consolidated multi-district proceeding in Minnesota, distinguishing apparel-based skin absorption claims from aqueous foam water pollution dockets.
  3. Plaintiffs argue thermal breakdown during fire suppression operations released free fluorochemicals directly through perspiration and open skin pores.
SourcesThe Cool Down: Judge says 3M, DuPont, and Honeywell must face Connecticut firefighters' PFAS claims (opens in new tab)

Mass Tort

Meta's $18B settlement established algorithmic design as a defective product — piercing Big Tech's immunity shield against child addiction lawsuits.

BackgroundSection 230 of the Communications Decency Act has long protected internet platforms from legal liability regarding third-party user content. Plaintiffs' attorneys bypassed that statutory shield by suing over algorithmic recommendations and engagement architecture rather than specific online speech.

Points
  1. The $18B settlement resolved a marquee bellwether trial in Oakland, California, brought on behalf of hundreds of public school districts.
  2. Plaintiffs successfully argued infinite scroll and push notifications operate as defective mechanical features designed to induce compulsive psychological dependence.
  3. More than 1,200 personal injury and municipal claims remain active across federal dockets targeting ByteDance, Snap, and Alphabet.
SourcesGen Re: Meta's $18 Billion Settlement – Key Takeaways for Insurers (opens in new tab)

Mass Tort

Gibson Dunn raided Paul Weiss's premier mass tort defense team — escalating an expensive talent war to defend Fortune 500 giants against multi-billion-dollar MDL claims.

BackgroundMultidistrict litigation consolidates thousands of personal injury lawsuits across the nation into a single federal venue for coordinated pretrial proceedings. Corporate defendants routinely pay tens of millions in legal fees to elite defense litigators to manage high-stakes bellwether jury trials.

Points
  1. The lateral group brings trial litigators Kimberly Branscome, Yahonnes Cleary, and Jonathan Tam into Gibson Dunn's product liability practice.
  2. The team previously served as lead trial counsel for Johnson & Johnson in nationwide talc disputes and Bayer in Roundup cancer trials.
  3. The recruitment comes as corporate clients confront record jury awards across pharmaceutical, consumer health, and chemical contamination dockets.
SourcesCDR News: Gibson Dunn poaches Paul Weiss mass tort and product liability heavyweights (opens in new tab)

Unlock the full brief

Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.

Or read free in the appDownload on the App Store